Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, Osaki T, Kasahara N, Uchino J, Sugiyama T, Ishihara S, Ishii H, Naruse I, Mori K, Kotake M, Kanazawa K, Minato K, Kagamu H, Kaira K. Yamaguchi O, et al. Among authors: uchino j. Cancer Chemother Pharmacol. 2020 Apr;85(4):761-771. doi: 10.1007/s00280-020-04055-7. Epub 2020 Mar 19. Cancer Chemother Pharmacol. 2020. PMID: 32193618
Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K. Katakami N, et al. Among authors: uchino j. Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4. Cancer. 2018. PMID: 29205286 Free PMC article. Clinical Trial.
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Nakao A, Uchino J, Igata F, On R, Ikeda T, Yatsugi H, Hirano R, Sasaki T, Tanimura K, Imabayashi T, Tamiya N, Kaneko Y, Yamada T, Nagata N, Watanabe K, Kishimoto J, Takayama K, Fujita M. Nakao A, et al. Among authors: uchino j. Invest New Drugs. 2018 Oct;36(5):903-910. doi: 10.1007/s10637-018-0617-6. Epub 2018 May 30. Invest New Drugs. 2018. PMID: 29846848 Clinical Trial.
Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment.
Uchino J, Nakao A, Tamiya N, Kaneko Y, Yamada T, Yoshimura K, Fujita M, Takayama K. Uchino J, et al. Medicine (Baltimore). 2018 Jun;97(23):e11081. doi: 10.1097/MD.0000000000011081. Medicine (Baltimore). 2018. PMID: 29879078 Free PMC article. Clinical Trial.
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
Chihara Y, Date K, Takemura Y, Tamiya N, Kohno Y, Imabayashi T, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K. Chihara Y, et al. Among authors: uchino j. Invest New Drugs. 2019 Apr;37(2):291-296. doi: 10.1007/s10637-018-0656-z. Epub 2018 Aug 18. Invest New Drugs. 2019. PMID: 30121935 Clinical Trial.
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Yoshimura A, Uchino J, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Takeda T, Hiranuma O, Hasegawa I, Kubota Y, Shiotsu S, Takumi C, Hiraoka N, Yamada T, Takayama K. Yoshimura A, et al. Among authors: uchino j. Medicine (Baltimore). 2018 Oct;97(40):e12660. doi: 10.1097/MD.0000000000012660. Medicine (Baltimore). 2018. PMID: 30290647 Free PMC article.
A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, Kuwako T, Naruse I, Nemoto K, Uchino J, Morozumi N, Ishihara S, Minato K, Hisada T. Imai H, et al. Among authors: uchino j. Lung Cancer. 2018 Dec;126:41-47. doi: 10.1016/j.lungcan.2018.10.014. Epub 2018 Oct 13. Lung Cancer. 2018. PMID: 30527191 Clinical Trial.
410 results